<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127880</url>
  </required_header>
  <id_info>
    <org_study_id>SLHN 2005-34</org_study_id>
    <nct_id>NCT01127880</nct_id>
  </id_info>
  <brief_title>Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax</brief_title>
  <official_title>The Role of Antibiotics in the Reduction of Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax: A Prospective, Double-Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Hospital, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's Hospital, Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of prophylactic antibiotics in patients
      with chest tubes for management of thoracic injuries in the reduction of the incidence of
      empyema as compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the medication (an antibiotic which is used to treat or prevent infections)
      will be compared with a placebo. A placebo is something that looks like a &quot;real&quot; medication,
      but it doesn't contain any active medication. As a participant in this study, you may receive
      the active medication (Cefazolin Sodium Injection or Clindamycin) or you may receive a
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of prophylactic antibiotics in reduction of empyema</measure>
    <time_frame>30 days</time_frame>
    <description>The primary objective of this study is to examine the efficacy of prophylactic antibiotics in patients with chest tubes for management of thoracic injuries in the reduction of the incidence of empyema as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pneumonia and/or development of resistant microorganisms</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary objectives include:
Incidence of pneumonia Incidence of development of resistant microorganisms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hemopneumothorax</condition>
  <condition>Pneumothorax</condition>
  <arm_group>
    <arm_group_label>Ancef 1 gm or Clindamycin 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B will receive .9% Normal Saline as a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ancef or Clindamycin</intervention_name>
    <description>1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic</description>
    <arm_group_label>Ancef 1 gm or Clindamycin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>.9% Normal Saline as a placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 16 years of age.

          2. Admission to Trauma, General Surgery, and/or Surgical Critical Care services.

          3. Traumatic pneumothorax, hemothorax or hemopneumothorax

        Exclusion Criteria:

          1. Pregnancy

          2. Open fracture

          3. Immunocompromised

          4. Require antibiotics for treatment of other injuries

          5. Chest tube placement greater than 72hrs after admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel McQuay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital and Health Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <last_update_submitted>May 20, 2010</last_update_submitted>
  <last_update_submitted_qc>May 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nathaniel McQuay, Jr., MD</name_title>
    <organization>St. Luke's Hospital and Health Network</organization>
  </responsible_party>
  <keyword>Traumatic Hemopneumothorax</keyword>
  <keyword>Thoracotomy</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumothorax</mesh_term>
    <mesh_term>Hemopneumothorax</mesh_term>
    <mesh_term>Hemothorax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 6, 2012</submitted>
    <returned>July 9, 2012</returned>
    <submitted>April 30, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

